Aligos Therapeutics, Inc. (ALGS) Q2 2024 Earnings
ALGS·Reported August 6, 2024·After market close
Aligos Therapeutics, Inc. reported Q2 2024 revenue of $1.1M. Diluted EPS came in at $0.75, beat the $-4.00 consensus by $4.75.
Revenue
$1.1M
Diluted EPS
$0.75beat by $4.75
Consensus: $-4.00
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about Aligos Therapeutics, Inc.'s Q2 2024 earnings report.
Aligos Therapeutics, Inc. (ALGS) reported Q2 2024 earnings on August 6, 2024 after market close.
Aligos Therapeutics, Inc. reported revenue of $1.1M and diluted EPS of $0.75 for Q2 2024.
EPS beat the consensus estimate of $-4.00 by $4.75.
You can read the 10-Q periodic report (0000950170-24-091828) directly on SEC EDGAR. The filing index links above go to sec.gov.